Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward
- PMID: 41266307
- PMCID: PMC12635168
- DOI: 10.1038/s41467-025-64887-w
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward
Abstract
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks such as altered reward processing and dependence. However, the mechanisms behind these effects remain unclear. Our data demonstrate that a single administration of the psychedelic psilocybin (PSI) reduces conditioned behavior and withdrawal induced by the opioid oxycodone (OXY) in male mice but not in females, and this effect is mediated via the 5-HT2A receptor (5-HT2AR). We show that the sex-specific attenuation of OXY preference is driven by 5-HT2AR activation in frontal cortex pyramidal neurons projecting to the nucleus accumbens (NAc). Additionally, PSI modulates epigenomic regulation following repeated OXY exposure and induces sex-specific NAc dendritic structural plasticity independently of 5-HT2AR. Notably, female frontal cortex and NAc show fewer changes at gene enhancer regions in response to PSI, repeated OXY, or combined PSI-OXY treatment compared to males, with the frontal cortex exhibiting more pronounced sex differences than the NAc at the epigenomic level. Together, these results provide new insights into the neural and epigenetic mechanisms of psychedelic-induced plasticity in OUD, while also highlighting sex differences in PSI's modulation of reward pathways and its therapeutic potential.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: J.G.-M. has received research support from Noetic Fund, Terran Biosciences, and Gonogo Solutions. A.M.J. had a consulting contract with Terran Biosciences. The remaining authors declare no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
- F31DA057818/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- R01DA058089/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- R01 GM143940/GM/NIGMS NIH HHS/United States
- R01GM143940/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- T32 DA007027/DA/NIDA NIH HHS/United States
- F31 DA057818/DA/NIDA NIH HHS/United States
- R01AA022537/U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- R01 MH111940/MH/NIMH NIH HHS/United States
- T32DA007027/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- R01MH084894/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R01 MH084894/MH/NIMH NIH HHS/United States
- R25 GM089614/GM/NIGMS NIH HHS/United States
- R01 DA056187/DA/NIDA NIH HHS/United States
- P30DA033934/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- R01 DA058089/DA/NIDA NIH HHS/United States
- P30 DA033934/DA/NIDA NIH HHS/United States
- R01MH111940/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R01DA056187/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- R25GM089614/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- P50 AA022537/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
